CCA
MYGN icon

Checchi Capital Advisers’s Myriad Genetics MYGN Stock Holding History

Checchi Capital Advisers’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-59
Closed -$2K – 917
2016
Q2 		$2K Hold
59
– – ﹤0.01% 1513
2016
Q1 		$2K Buy
+59
New +$2.22K ﹤0.01% 1520

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Checchi Capital Advisers's MYGN Position: Q3 2016 in Review

Checchi Capital Advisers sold out of Myriad Genetics (MYGN) in Q3 2016, closing a stake of 59 shares — an estimated $2K sold.

Checchi Capital Advisers first reported a position in MYGN in Q1 2016 and held it in 2 quarters. The position peaked at $2K in Q2 2016. 223 funds tracked by Wall St. Rank hold MYGN as of Q3 2016.

  • Checchi Capital Advisers reported no remaining Myriad Genetics position as of Q3 2016 after selling out during the quarter.
  • Checchi Capital Advisers sold 59 Myriad Genetics shares in Q3 2016, an estimated $2K.
  • Checchi Capital Advisers first reported a position in Myriad Genetics in Q1 2016 and held it in 2 quarters.
  • Checchi Capital Advisers's Myriad Genetics position peaked at $2K in Q2 2016.
  • 223 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2016.

Based on Checchi Capital Advisers's 13F filing for Q3 2016, filed 10 Nov 2016.